期刊
MOLECULAR CANCER THERAPEUTICS
卷 20, 期 9, 页码 1533-1541出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-21-0115
关键词
-
类别
资金
- Intramural Research Program (IRP) of the National Institutes of Health, National Cancer Institute (NCI)
- Center for Cancer Research (CCR), Antibody Engineering Program [011891]
Antibody-based immunotherapies have shown efficacy in cancer treatment, but their targets are limited. Research has shown that short peptides from intracellular targets could be potential immunotherapy targets. TCRm antibodies are a promising new direction, and future clinical studies will help further understand their mechanisms of action.
Antibody-based immunotherapies show clinical effectiveness in various cancer types. However, the target repertoire is limited to surface or soluble antigens, which are a relatively small percentage of the cancer proteome. Most proteins of the human proteome are intracellular. Short peptides from intracellular targets can be presented by MHC class I (MHC-I) molecules on cell surface, making them potential targets for cancer immunotherapy. Antibodies can be developed to target these peptide/MHC complexes, similar to the recognition of such complexes by the T-cell receptor (TCR). These antibodies are referred to as T-cell receptor mimic (TCRm) or TCR-like antibodies. Ongoing preclinical and clinical studies will help us understand their mechanisms of action and selection of target epitopes for immunotherapy. The present review will summarize and discuss the selection of intracellular antigens, production of the peptide/MHC complexes, isolation of TCRm antibodies for therapeutic applications, limitations of TCRm antibodies, and possible ways to advance TCRm antibody-based approaches into the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据